Traditional Quality
To learn more about Quality Measures available in Practice Insights, click on a measure below.
MIPS # PIMSH1 Advance Care Planning in Metastatic DiseaseMIPS # PIMSH2 Utilization of GCSF in Metastatic Colorectal CancerMIPS # PIMSH 4 Patient Reported Pain ImprovementMIPS # PIMSH 9 Supportive Care Drugs in Last 14 DaysMIPS # PIMSH 10 Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting DrugsMIPS # PIMSH 13 Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted TherapyMIPS # PIMSH 15 Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center - Avoidance of OveruseMIPS # PIMSH 16 Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion CenterMIPS #47 Advance Care PlanningMIPS #104 Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate CancerMIPS #130 Documentation of Current Medications MIPS #134 Depression Screening--MIPS CQMMIPS #134 Depression Screening--eCQMMIPS #143 Pain Intensity QuantifiedMIPS #144 Pain Care PlanMIPS # 226 Tobacco Screening and CessationMIPS #236 Controlling High Blood PressureMIPS #238 High Risk Medications in Older AdultsMIPS # 374 Closing the Referral LoopMIPS #450 Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast CancerMIPS #451 RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody TherapyMIPS #452 Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal AntibodiesMIPS #453 Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life MIPS # 457 Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 daysMIPS # 462 Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation TherapyMIPS # 487 Screening for Social Drivers of Health